Skip to main content

Why use Insulin Pump Therapy?

90%

Fewer injections 

Lower

HbA1c5,6

Therapy System Components

Bomba de insulina

Therapy System Components

Insulin pump

Discover more

Infusion set

Therapy System Components

Infusion set

Discover more

Guardian 4 Sensor Transmitter

Therapy System Components

CGM sensor (Continous Glucose Monitoring)

Discover more

Phone App

Therapy System Components

Smartphone App

Discover more

Insulin Pump Therapy Benefits

Insulin pump therapy offers several clinical benefits over multiple daily injection therapy. With our pump and sensor system, you’re more likely to:

Keep your glucose levels in range1,2,3,4

Lower
HbA1c5,6

Higher time in
range1,2,5,8

Fewer hypoglycaemic
events7

Live more,worry less

0%

Less 
injections 

0%

Worry less 
about highs9

0%

Worry less about low 
during sleep9

Frequently asked questions

The device is safe, and can be used in all types of situations (sport, beach, going out) and insulin is simply delivered to your body through a thin tube. Thanks to smart accessories available today, it can be comfortably worn during school, exercise, formal occasions and everyday life.

Insulin pumps can be easily worn on or under your clothes very securely. The pump can also be detached for activities like swimming, showering and exercise so you can continue to live your life.

You can have your insulin pump with you whilst exercising. Temporary targets/basal rates are available (depending on pump model), plus MiniMed™ insulin pump systems are waterproof , providing more flexibility while you live your life to the fullest.

It is small enough so it can be easily carried on a belt, in a pocket or even attached to a bra. The pump is about the same size as a pack of playing cards and similar in weight to an average lemon.

There are many ways your insulin pump can be worn. Whether at school, at work,at a formal occasions or just in everyday life, your insulin pumps can be easily worn on or under your clothes very securely. The pump can also be detached for activities like contact sport, showering and exercise.

MiniMed™ insulin pumps are waterproof  so you can still wear your pump when you are going swimming, bathing or in the shower. If you wish to disconnect, we recommend that this is for no longer than 1 hour. Reattach as soon as you’re done, and if you’ve had a vigorous swim remember to check your blood glucose levels.

References

  1. Carlson, A.L. et al. 97-P- Safety and glycaemic outcomes of the MiniMed™ AHCL System in subjects with T1D. 80th ADA International Conference, June 2020, Chicago
  2. Collyns .O. et al. 199-OR- Improved glycaemic Outcomes with MiniMed™ AHCL Delivery.  80th ADA International Conference, June 2020, Chicago
  3. Agiostratidou, G. et al. Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care 2017; 40(12):1622–1630.
  4. Danne T. et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care 2017; 40(12):1631-1640.
  5. Bergenstal, R. M. et al.Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes Jama. 2016; 316 (13): 1407 – 1408
  6. J. C. Pickup and A. J. Sutton Severe hypoglycaemia and glycemic control in Insulin Dependant Diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion Diabetic Medicine 2008 :25, 765–774.
  7. Bergenstal RM1, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care. 2011 Nov;34(11):2403-5. doi: 10.2337/dc11-1248. Epub 2011 Sep 20.
  8. Assumes four injections per day for 30 days and one infusion set change every three days.
  9. Medtronic data on file. Pivotal Trial (Age 14-75). N=157. 2020; 16 US sites.
  • 1.Carlson, A.L. et al. 97-P- Safety and glycaemic outcomes of the MiniMed™ AHCL System in subjects with T1D. 80th ADA International Conference, June 2020, Chicago
  • 2.Collyns .O. et al. 199-OR- Improved glycaemic Outcomes with MiniMed™ AHCL Delivery.  80th ADA International Conference, June 2020, Chicago
  • 3.Agiostratidou, G. et al. Standardizing Clinically Meaningful Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus Report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care 2017; 40(12):1622–1630.
  • 4.Danne T. et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care 2017; 40(12):1631-1640.
  • 1.Carlson, A.L. et al. 97-P- Safety and glycaemic outcomes of the MiniMed™ AHCL System in subjects with T1D. 80th ADA International Conference, June 2020, Chicago
  • 2.Collyns .O. et al. 199-OR- Improved glycaemic Outcomes with MiniMed™ AHCL Delivery.  80th ADA International Conference, June 2020, Chicago
  • 5.Bergenstal, R. M. et al.Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes Jama. 2016; 316 (13): 1407 – 1408
  • 1.Carlson, A.L. et al. 97-P- Safety and glycaemic outcomes of the MiniMed™ AHCL System in subjects with T1D. 80th ADA International Conference, June 2020, Chicago
  • 2.Collyns .O. et al. 199-OR- Improved glycaemic Outcomes with MiniMed™ AHCL Delivery.  80th ADA International Conference, June 2020, Chicago
  • 5.Bergenstal, R. M. et al.Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes Jama. 2016; 316 (13): 1407 – 1408
  • 8.Assumes four injections per day for 30 days and one infusion set change every three days.
  • 5.Bergenstal, R. M. et al.Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes Jama. 2016; 316 (13): 1407 – 1408
  • 6.Assumes four injections per day for 30 days and one infusion set change every three days.
  • 7.Bergenstal RM1, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA; STAR 3 Study Group. Sensor-augmented pump therapy for A1C reduction (STAR 3) study: results from the 6-month continuation phase. Diabetes Care. 2011 Nov;34(11):2403-5. doi: 10.2337/dc11-1248. Epub 2011 Sep 20.
  • 9.Medtronic data on file. Pivotal Trial (Age 14-75). N=157. 2020; 16 US sites.
  • † Assumes four injections per day for 30 days and one infusion set change every three days
  • * Compared to MiniMed™ 670G system
  • **For MiniMed™ 600 & 700 series devices only: At time of manufacture and when the reservoir and tubing are properly inserted, your pump is waterproof. It is protected against the effects of being underwater to a depth of up to 12 feet (3.6 meters) for up to 24 hours. This is classified as IPX8 rating. See user guide for details.